Form 4 for DNLI Denali Therapeutics Inc.

Accepted 2025-11-06 00:00:00 ET · period of report 2025-11-04 · accession 0001816206-25-000007 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2025-11-06	2025-11-04	DNLI	Van Hauwermeiren Timothy	Dir	A - Grant	$0.00	+10.6K	10.6K	New	$0
D	2025-11-06	2025-11-04	DNLI	Van Hauwermeiren Timothy	Dir	A - Grant	$0.00	+31.9K	31.9K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2025-11-04	A	A	10,632	$0.00	10,632	D	—	—	(F1) Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. The RSU award vests over a four-year period, with 1/4th of the shares vesting on each anniversary of the grant date (or, for the last tranche that otherwise would vest on the fourth anniversary of the grant date, on such anniversary or, if earlier, on the day prior to the Company's next annual meeting of stockholders occurring after the third anniversary of the grant date), provided that he remains a non-employee director through the applicable vesting date. (F2) Includes 10,632 unvested RSUs.
2	Derivative	Stock Option (right to buy)	2025-11-04	A	A	31,897	$0.00	31,897	D	$14.92 · — to 2034-11-04	31,897 Common Stock	(F3) 25% of the shares subject to the option shall vest on November 4, 2026, and an additional 1/48 of the shares subject to the option vest each month thereafter, subject to the Reporting Person remaining a non-employee director of the Issuer through each such date